Jodee Karlowsky’s Story: Finding Strength in a Collective Voice

ALS Caregiver, ALS Action Canada Member and Membership Committee Member When someone is diagnosed with ALS, the impact extends far beyond the person living with the disease. Families find themselves navigating an entirely new reality, often watching the lives they had planned change in ways they could never have anticipated. For Jodee Karlowsky, whose husband […]
Inspired to Act: Caryn Lieberman on Courage and Advocacy

Some stories stay with you long after the interview ends. For Global News Toronto journalist Caryn Lieberman, Louis Del Re’s story is one of them. Caryn first learned about Louis, an ALS Action Canada Board Director, through his uncle, a Toronto police officer she was working with on a story. Moved by what she heard […]
A Patient Perspective on ALS Clinical Trials and Timely Access
How much evidence should be required before people living with ALS can access a promising new therapy?
In a newly published Reader Response in Neurology, Dr. Andrew Darke, an ALS Action Canada Advocacy Committee Member, responds to a recent article examining what its authors describe as a “credibility gap” in ALS clinical trials, due to what it describes as a “Clinical Trial Industrial Complex” involving ALS neurologists and manufacturers of new drugs for ALS.
Challenging Barriers to ALS Treatment Access: Bringing Our Patient Voice to Canada’s Drug Agency
From time to time, we hear of pALS who are not eligible to get Radicava under their provincial or private insurance plan. Recently we heard of a pALS who had been on Radicava, but were later told they were no longer eligible to receive it. The reason for this is the criteria for who is eligible for drugs, and who can continue to receive them under the provincial drug benefit plans. These criteria are developed by Canada’s Drug Agency (CDA), which is a separate agency from Health Canada which approves drugs as safe and effective
to be marketed.
My ALS Journey: Terry’s Story

After years of searching for answers, Terry Loustel was diagnosed with ALS in 2022. In his own words, Terry shares his journey—from receiving his diagnosis to navigating life with ALS—and why he has chosen to use his voice to advocate for the ALS community.
Shawn’s Story: Choosing Hope, Living Fully

At 57, Shawn lives in a small town in British Columbia’s northern Okanagan. He enjoys the beauty of the region and remains focused on living life to the fullest, despite an ALS diagnosis that arrived after a long and uncertain journey.
Shawn first noticed something was wrong in May 2022 when he developed a weak pinch grip in his left hand. What followed was more than a year of appointments, referrals, tests, and alternative explanations.
Finding Courage, Purpose, and Community While Living with ALS

Amanda Tam shares her perspective on living with ALS, the importance of accelerating research, and what keeps her moving forward. Through honesty, advocacy, and awareness, she is helping build understanding and community while ensuring the experiences of people living with ALS remain at the centre of conversations about care, research, and support.
Volunteer Spotlight: Turning Advocacy into Action

During National Volunteer Week, we recognize volunteers who are helping drive progress toward ending ALS. Chris May brings decades of advocacy experience to ALS Action Canada’s Advocacy Committee – now with a deeply personal mission. Living with ALS, Chris is using his knowledge of government to help drive awareness, influence change, and push for progress toward ending ALS.
Courage to Fight: A Movement to End ALS Webinar Replay Featuring Patient Living with ALS, Louis Del Re

Hear from Louis Del Re, a person living with ALS, who has channelled his diagnosis into fundraising for the cause, and Leigh Naturkach, Executive Director of ALS Action Canada and Cause Leader of the ALS Super Fund, as they share what courage looks like up close. Watch the webinar
Feedback on Evolving Patient Group Input Submissions into the Drug Reimbursement Review Process
ALS Action Canada Submission to the Canada Drug Agency 1.1 What suggestions do you have for evolving the patient input process to focus on what is needed to support deliberations on the deliberative framework domains? The Advocacy Committee of ALS Action Canada (ALSAC) very much appreciates the extensive efforts being made by CDA’s Engagement Group […]